The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 24, 2025

Filed:

Apr. 20, 2018
Applicant:

Iomx Therapeutics Ag, Martinsried, DE;

Inventors:

Antonio Sorrentino, Heidelberg, DE;

Philipp Beckhove, Regensburg, DE;

Tillmann Michels, Heidelberg, DE;

Nisit Khandelwal, Martinsried, DE;

Michael Boutros, Heidelberg, DE;

Marco Breinig, Schriesheim, DE;

Peter Sennhenn, Martinsried, DE;

Sebastian Meier-Ewert, Martinsried, DE;

Valentina Volpin, Regensburg, DE;

Ayse Nur Menevse, Regensburg, DE;

Assignee:

IOMX THERAPEUTICS AG, Martinsried, DE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/506 (2006.01); A61K 31/7088 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); G01N 33/50 (2006.01); G01N 33/574 (2006.01); A61B 10/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1137 (2013.01); A61K 31/506 (2013.01); A61K 31/7088 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); G01N 33/5047 (2013.01); G01N 33/57492 (2013.01); A61B 10/0041 (2013.01); C12N 2310/122 (2013.01); C12N 2320/31 (2013.01);
Abstract

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.


Find Patent Forward Citations

Loading…